2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle 
05/30/18Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Jefferies 2018 Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, June 6, at 10:00 a.m. Eastern Time. A webcast of the presentation will be available live and for 30 days foll... 
Printer Friendly Version
05/03/18Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
BURLINGAME, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the first quarter ended March 31, 2018, and provided a business update. “We made important progress in advancing our clinical programs and building our pipeline, with several notable developments in the first quarter that rein... 
Printer Friendly Version
04/26/18Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
Three-arm Trial Will Evaluate CPI-006 as Monotherapy, in Combination with CPI-444 Adenosine Antagonist and in Combination with Pembrolizumab BURLINGAME, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it is enrolling patients in a multicenter Phase 1/1b clinical trial of CPI-006, a humanized monoclonal... 
Printer Friendly Version
03/12/18Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
BURLINGAME, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target crucial enzymes and proteins in the immune system to treat patients with cancer, today announced the completion of its previously announced underwritten public offering of 8,117,647 shares of its common stock, which includes the exercise in full b... 
Printer Friendly Version
03/08/18Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BURLINGAME, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target crucial enzymes and proteins in the immune system to treat patients with cancer, today announced the pricing of an underwritten public offering of 7,058,824 shares of its common stock at a price to the public of $8.50 per share, for gross proceeds... 
Printer Friendly Version
03/07/18Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
BURLINGAME, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target crucial enzymes and proteins in the immune system to treat patients with cancer, today announced that it has commenced an underwritten public offering of up to $50.0 million shares of its common stock. All of the shares to be sold in the offering ... 
Printer Friendly Version
03/06/18Corvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018
BURLINGAME, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Cowen and Company 38th Annual Health Care Conference 2018 in Boston, Massachusetts. The presentation is scheduled for Tuesday, March 13, at 11:20 a.m. Eastern Time. A webcast of the presentation will be availa... 
Printer Friendly Version
03/01/18Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year ended December 31, 2017, and provided a business update. “In 2017, Corvus continued to make progress in expanding its pipeline of product candidates. We have enrolled more than 235 patients on our... 
Printer Friendly Version
02/01/18Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
Company’s Investigational Small Molecule Inhibitor Demonstrates Safety and Activity in Canine Spontaneous T-Cell Lymphoma BURLINGAME, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced new data from an ongoing preclinical study of its investigational small molecule T-cell signaling pathway inhibitor. Results sh... 
Printer Friendly Version